Meeting
2017 ASCO Annual Meeting
A phase II study of pembrolizumab for patients with previously treated advanced thymic epithelial tumor.
Authors
Jinhyun Cho
Inha University Hospital, Incheon, Republic of Korea
Jinhyun Cho , Myung-Ju Ahn , Kwai Han Yoo , Hansang Lee , Hee Kyung Kim , Mi Hwa Heo , Joo Hyun Hong , Jong-Mu Sun , Se-Hoon Lee , Jin Seok Ahn , Keunchil Park
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Discussion Session
Session Title
Lung Cancer—Non-Small Cell Local-Regional/Small Cell/Other Thoracic Cancers
Track
Lung Cancer
Sub Track
Thymic Malignancies
Clinical Trial Registration Number
NCT02607631
Citation
J Clin Oncol 35, 2017 (suppl; abstr 8521)
DOI
10.1200/JCO.2017.35.15_suppl.8521
Abstract #
8521
Poster Bd #
257
Abstract Disclosures
Similar Posters
Poster
2022 ASCO Annual Meeting
Lenvatinib for the treatment of thymic epithelial tumors (TETs): A real-life multicenter experience.
First Author: Jose Carlos Benitez
Poster
2020 ASCO Virtual Scientific Program
A Big Ten Cancer Research Consortium phase II trial of pembrolizumab with carboplatin and paclitaxel for advanced or recurrent endometrial cancer.
First Author: Mario Javier Pineda
Poster
2020 ASCO Virtual Scientific Program
Low-dose oral etoposide is an active option for patients with heavily pre-treated thymic epithelial tumors.
First Author: Margaret Ottaviano
Poster
2018 ASCO Annual Meeting
A phase II study of regorafenib in patients with thymic epithelial tumours previously treated with chemotherapy.
First Author: Matteo Perrino